Increased insulin-stimulated endothelin-1 release is a distinct vascular phenotype distinguishing Cushing's disease from metabolic syndrome - PubMed (original) (raw)
Increased insulin-stimulated endothelin-1 release is a distinct vascular phenotype distinguishing Cushing's disease from metabolic syndrome
Emanuela Setola et al. Clin Endocrinol (Oxf). 2007 Apr.
Abstract
Objective: Although much is known about the anti-inflammatory effects of an acute corticosteroid therapy, little is known about the effects on chronic hypercortisolism on endothelial dysfunction and proinflammatory alterations in patients with Cushing's disease (CD).
Patients and methods: We studied 9 patients with CD, 10 patients with metabolic syndrome and 27 normal controls. The tests consisted of an intravenous bolus of 0.1 U/kg insulin combined with a euglycaemic clamp technique with an arterialized forearm and assessment of the training parameters deep-venous balance of forearm glucose uptake (as an index of insulin sensitivity); NO(x) (nitric oxide end-products), c-GMP (second messenger of nitric oxide) and endothelin-1 release, as indices of endothelial function and proinflammatory systemic markers.
Results: Forearm glucose uptake incremental area was significantly lower in Cushing's disease and in the metabolic syndrome than in controls, suggesting a state of severe insulin resistance. Compared to controls and to the metabolic syndrome, basal and insulin-stimulated NO(x) release incremental areas were significantly reduced in Cushing's disease, while forearm c-GMP release was similarly decreased in CD and metabolic syndrome. By contrast, endothelin-1 incremental areas after insulin bolus were significantly higher in CD than in controls and the metabolic syndrome, in the presence of increased TNF-alpha, IL-6 and CRP levels. Forearm glucose uptake incremental area significantly correlated with NO(x) incremental area, forearm c-GMP release incremental area, TNF-alpha levels and ET-1 incremental area.
Conclusions: In patients with CD, supraphysiological insulin levels are not able to overcome the insulin resistance due to chronic hypercortisolism. Furthermore, an increased proatherogenic risk profile is characterized by decreased nitric oxide synthesis and activity, enhanced endothelin-1 levels and increased proinflammatory markers.
Similar articles
- Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission.
Giordano R, Picu A, Marinazzo E, D'Angelo V, Berardelli R, Karamouzis I, Forno D, Zinnà D, Maccario M, Ghigo E, Arvat E. Giordano R, et al. Clin Endocrinol (Oxf). 2011 Sep;75(3):354-60. doi: 10.1111/j.1365-2265.2011.04055.x. Clin Endocrinol (Oxf). 2011. PMID: 21521323 - Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy.
Monti LD, Setola E, Fragasso G, Camisasca RP, Lucotti P, Galluccio E, Origgi A, Margonato A, Piatti P. Monti LD, et al. Am J Physiol Endocrinol Metab. 2006 Jan;290(1):E54-E59. doi: 10.1152/ajpendo.00083.2005. Epub 2005 Sep 20. Am J Physiol Endocrinol Metab. 2006. PMID: 16174656 Clinical Trial. - The metabolic syndrome and cardiovascular risk in Cushing's syndrome.
Pivonello R, Faggiano A, Lombardi G, Colao A. Pivonello R, et al. Endocrinol Metab Clin North Am. 2005 Jun;34(2):327-39, viii. doi: 10.1016/j.ecl.2005.01.010. Endocrinol Metab Clin North Am. 2005. PMID: 15850845 Review. - Insulin resistance, metabolic syndrome and vascular diseases: update on mechanistic linkages.
Lteif A, Mather K. Lteif A, et al. Can J Cardiol. 2004 Aug;20 Suppl B:66B-76B. Can J Cardiol. 2004. PMID: 15309208 Review.
Cited by
- Endocrine Disorders and Peripheral Arterial Disease - A Series of Reviews Cushing Syndrome-Cortisol Excess.
Poredoš P, Schernthaner GH, Blinc A, Mikhailidis DP, Jensterle M, Anagnostis P, Antignani PL, Studen KB, Šabović M, Ježovnik MK. Poredoš P, et al. Curr Vasc Pharmacol. 2024;22(4):236-241. doi: 10.2174/0115701611272145231106053914. Curr Vasc Pharmacol. 2024. PMID: 38038006 Review. - Cardiovascular evaluation and endothelial dysfunction in Cushing syndrome following remission: a prospective study.
Hacioglu A, Firat ST, Caglar AS, Karaca Z, Kalay N, Taheri S, Tanriverdi F, Selcuklu A, Unluhizarci K, Kelestimur F. Hacioglu A, et al. J Endocrinol Invest. 2024 Mar;47(3):645-653. doi: 10.1007/s40618-023-02183-4. Epub 2023 Aug 30. J Endocrinol Invest. 2024. PMID: 37648907 - Active Cushing Disease Is Characterized by Increased Adipose Tissue Macrophage Presence.
Lee IT, Atuahene A, Egritag HE, Wang L, Donovan M, Buettner C, Geer EB. Lee IT, et al. J Clin Endocrinol Metab. 2019 Jun 1;104(6):2453-2461. doi: 10.1210/jc.2018-02552. J Clin Endocrinol Metab. 2019. PMID: 30722035 Free PMC article. - Vascular Dysfunction in Horses with Endocrinopathic Laminitis.
Morgan RA, Keen JA, Walker BR, Hadoke PW. Morgan RA, et al. PLoS One. 2016 Sep 29;11(9):e0163815. doi: 10.1371/journal.pone.0163815. eCollection 2016. PLoS One. 2016. PMID: 27684374 Free PMC article. - Relationship between the Balance of Hypertrophic/Hyperplastic Adipose Tissue Expansion and the Metabolic Profile in a High Glucocorticoids Model.
Zubiría MG, Alzamendi A, Moreno G, Portales A, Castrogiovanni D, Spinedi E, Giovambattista A. Zubiría MG, et al. Nutrients. 2016 Jul 2;8(7):410. doi: 10.3390/nu8070410. Nutrients. 2016. PMID: 27384583 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous